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Abstract
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble 
CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the ‘early’, the ‘high-risk’, and the 
‘ibrutinib-treated’. The ‘high-risk’ patients had significantly higher sCD52 levels than the ‘early’ 
patients. For the ‘early’ patients, high sCD52 levels were associated with a significantly shorter 
time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or 
beta-2-microglobulin were found; in a cox multivariate analysis of the ‘early’ patients, sCD52 and 
IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 
decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced 
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ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of 
CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects 
disease activity and potentially treatment efficacy in CLL.
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Introduction
The CD52 molecule is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein of 
approximately 29 kDa. It is comprised of only 12 amino acids with a large carbohydrate 
domain [1,2]. CD52 is expressed on virtually all hematopoietic cells at different levels; low 
levels on stem cells and high levels on lymphocytes and neoplastic B cells [3]. The molecule 
can be released by phospholipase C from the surface of immune cells as soluble CD52 
(sCD52), which has been shown to have inhibitory effects on T cells via Siglec-10 [4]. In 
chronic lymphocytic leukemia (CLL), sCD52 can be shed from CLL cells in vitro and can 
be bound by the anti-CD52 antibody alemtuzumab [5]. The biological function of the 
glycoprotein in patients with CLL remains unknown.
After induction treatment with fludarabine, cyclophosphamide and rituximab (FCR), sCD52 
levels predict progression and are proposed as a marker for minimal residual disease [6]. As 
CD52 is targeted by alemtuzumab, a correlation between the effect of alemtuzumab and 
CD52 expression has been sought. In the CLL2H trial of alemtuzumab consolidation for 
patients with fludarabine refractory CLL, high CD52 mRNA levels predicted a shorter 
overall and progression-free survival upon alemtuzumab treatment [7]. The Bruton’s 
tyrosine kinase (BTK) inhibitor ibrutinib approved for treatment of CLL, targets the B-cell 
receptor (BCR) pathway. It is highly efficacious, also in patients with deletion of the short 
arm of chromosome 17 (del(17p)) in the front line and relapse setting [8,9]. No studies have 
yet investigated sCD52 levels in relation to BCR-targeted treatment. We here address the 
correlation of sCD52 levels with prognostic factors in patients with CLL at diagnosis/




Blood samples from 111 patients with CLL and 45 healthy blood donors were included. 
Three CLL cohorts were studied. Cohort 1 (‘early’): 44 consecutive, unselected patients 
referred to Rigshospitalet, Copenhagen, Denmark in 2014, mainly at diagnosis (77%); 
cohort 2 (‘high-risk’): 42 patients selected for high-risk features (unmutated IGHV, and/or 
with del(17p), del(11q) or trisomy 12 by FISH), and in need of treatment according to 
IWCLL guidelines and enrolled in the HOVON68 first-line trial [10] (trialregister.nl: 
NTR529); cohort 3 (‘ibrutinib-treated’): 25 patients with advanced CLL in need of 
treatment, included in a phase II trial of single agent ibrutinib at the National Institutes of 
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Health (NIH), Bethesda, MD(ClinicalTrials.gov: NCT01500733) [8]. Furthermore, blood 
samples from four additional treatment naïve patients with unmutated IGHV status from 
NIH were included only for in vitro stimulation assays.
The study was approved by the ethical committees in Denmark (Regional ethics committee, 
Capital region of Denmark), The Danish Data protection agency, all participating countries 
in HOVON68, and at NIH (Bethesda, MD), and was performed in accordance with the 
declaration of Helsinki. Anonymized blood samples from healthy blood donors were 
provided by the Department of Immunology at Rigshospitalet, Copenhagen, Denmark with 
approval for research purposes. Clinical data were collected from patient medical records at 
Rigshospitalet, NIH, and from the HOVON database.
Samples
Plasma from cohort 1 and 2 was stored at −20 °C, serum from cohort 3 at −80 °C. Due to 
differences in handling and storage of samples that may influence protein levels we 
abstained from comparing plasma and serum values across cohorts. Thus, serum samples 
from cohort 3 were only used for analyses of sCD52 during treatment (n = 11) and as 
baseline values (n = 25).
ELISA and other analyses
sCD52 was quantified in plasma or serum by a commercial CD52 ELISA kit (CSB-
EL004943HU, Cusabio Biotech, China) following the manufacturer’s instructions. Values 
for sCD52 were extrapolated from a standard curve using Curve Expert Professional 
software version 2.0.3 (www.curveexpert.net). The kit was validated by western blot as 
described in the supplement (Figure S1, S2(A–C)).
Fluorescence in situ hybridization (FISH), IGHV mutational status, as well as the full 
protocol for affinity chromatography, anti-IgM stimulation, and Western blotting is provided 
in the supplement.
Statistical analyses
The statistical analyzes were performed in SAS 9.3 and SAS enterprise Guide 5.1 software 
(SAS institute, Cary, NC). Graphical presentations were performed in Graph Pad Prism 5 
(GraphPad software Inc., La Jolla, CA). Data were log transformed to convey a normal 
distribution. Samples below quantification limit of the ELISA were set to half the value of 
the lower limit of quantification of the assay (78ng/mL) for group-wise comparisons, and 
were not included in linear regression analysis. If samples were below the detection limit of 
the ELISA, they were valued as ‘0’. The median sCD52 for each cohort was used as cutoff 
value for dichotomization. Linear mixed models [11] were applied for analyses of 
correlations over time. Cox proportional hazards models were used for testing the 
independent and additive effects of sCD52. For specific analyses see figure legends. p 
Values were two-sided and considered significant if <.05.
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We evaluated sCD52 as an indicator of disease activity in different cohorts of patients with 
CLL. The clinical characteristics of the three cohorts are summarized in Table 1. The 
unselected ‘early’ cohort consisted of untreated, mainly stage A, and low-risk patients with 
CLL. The ‘high-risk’ cohort was selected for younger patients, mainly in stage B/C, with 
higher white blood cell counts (WBC) and beta-2-microglobulin (β2m) levels compared to 
the ‘early’ cohort. The ‘ibrutinib-treated’ cohort was selected for advanced CLL with 
untreated or relapsed/refractory disease with either TP53 aberrations or age above 65 years.
We first observed that levels of sCD52 in plasma were higher in patients with CLL (median 
365 ng/mL, interquartile range (IQR) [229–617.6]) than in healthy blood donors (median 
114 ng/mL, IQR [87–168]), (p < .0001, Figure 1(A)). Among patients with CLL, however, 
sCD52 levels were significantly higher for ‘high-risk’ patients (median 628 ng/mL, IQR 
[472–798]), as compared to ‘early’ patients (median 243 ng/mL, IQR [155–320]) (p < .0001, 
Figure 1(B)). We then assessed the correlation between sCD52 levels and known prognostic 
factors. Regarding clinical stage, in ‘early’ CLL, the few patients with Binet stage B/C had 
largely the same low sCD52 levels as those with Binet stage A, despite a statistical 
difference (p = .04, Figure 1(C)). In ‘high-risk’ CLL, sCD52 levels were similarly high in 
Binet stages A and B/C (p = .21, Figure 1(C)). Regarding IGHV mutational status, in ‘early’ 
CLL, no difference in sCD52 levels was found between patients with mutated (M) vs. 
unmutated (UM) IGHV (p = .59, data not shown). In contrast, in ‘high-risk’ CLL, sCD52 
levels were significantly higher in patients with M-IGHV compared to UM-IGHV (p = .004, 
data not shown). However, these patients all had adverse FISH findings. In general, sCD52 
levels did not correlate with cytogenetic aberrations in ‘early’ CLL (One-way ANOVA p = .
20, data not shown) or in ‘high-risk’ CLL (One-way ANOVA, p = .13, data not shown). 
Beta2-microglobulin did not correlate with sCD52 in either ‘early’ or ‘high-risk’ patients, 
respectively (p = .78, p = .70 resp. data not shown) or with the WBC (p = .54, p = .22, 
respectively Figure 1(D)).
To assess whether sCD52 had prognostic impact in the unselected patients with ‘early’ CLL, 
we analyzed the effect on time to the first treatment (TTFT): Despite a median follow-up of 
only 11 months, patients with sCD52 levels above median had a significantly shorter TTFT 
than those with sCD52 below median (p = .02, Figure 2(A)). As expected, IGHV status 
predicted for TTFT as well (p = .0002, data not shown). In a model including both sCD52 
levels and IGHV status, sCD52 levels retained independent significance by cox regression 
analysis (p = .02). Thus, the combination of sCD52 and IGHV allowed for a better 
discrimination between aggressive and indolent disease at diagnosis (Figure 2(B)).
We then analyzed sCD52 levels before and during treatment with chemo-immunotherapy. 
Following therapy with fludarabine and cyclophosphamide alone (FC) or in combination 
with alemtuzumab (FCA), the WBC and sCD52 levels decreased in parallel over time (p < .
0001, Figure 3(A)). To address whether sCD52 levels simply reflected the WBC, we 
included a cohort of ibrutinib-treated patients. During ibrutinib-induced lymphocytosis, 
sCD52 levels still decreased in parallel with a decrease in overall tumor burden including 
lymph nodes, spleen, and bone marrow [12] (Figure 3(B)). High pretreatment sCD52 levels 
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correlated with larger LN size (p = .04, Figure S3A) and lower absolute lymphocyte counts 
(ALC, p = .04, Figure S3B) as well as CD38 positivity (p = .005, Figure S3C). Patients with 
high sCD52 levels at baseline had a more efficient LN reduction during ibrutinib treatment 
(p = .009, Figure 3(C)). Even when incorporating LN size pretreatment (large LN size 
correlating with increased LN reduction) in a linear mixed model, pretreatment sCD52 levels 
retained a significant correlation with LN reduction (sCD52 p = .048, LN size p = .003). Of 
note, only two patients had progression on ibrutinib; both harbored del(17p), had UM-IGHV, 
and very low levels of sCD52 pretreatment (serum sCD52 = 0ng/mL). In vitro stimulation of 
primary CLL cells with anti-IgM, resembling the BCR-activated state of CLL cells in the 
microenvironment [13], significantly increased the level of sCD52 in the supernatants as 
compared to untreated cells (p = . 004, Figure 3(D)). Thus, high sCD52 levels may identify 
patients with more active CLL that responds well to ibrutinib; while the decrease of sCD52 
levels during treatment reflects treatment efficacy with both chemo-immunotherapy and 
ibrutinib.
Discussion
sCD52 is a rather unnoticed tumor marker in CLL where the levels are much higher than in 
healthy blood donors [5,14]. Despite the recently published prognostic indices such as the 
CLL-IPI [15], there is still a need for biological markers of disease activity that relates to 
treatment effect. We here demonstrate a correlation of sCD52 levels with the aggressiveness 
of CLL disease and with treatment effectiveness in differing disease compartments following 
conventional chemo-immunotherapy as well as ibrutinib. The perspective of sCD52 as a 
tumor marker in the era of targeted treatment for CLL is thus broadened.
Our finding of increased sCD52 levels in ‘progressive CLL’ in need of treatment, suggest 
that sCD52 levels possibly reflect disease aggressiveness, progressive disease or disease 
burden, independently of e.g. β2m. A previous study showed the prognostic impact of 
sCD52 levels on overall survival in a mixed population of both treatment naïve and relapsed/
refractory patients with CLL [5]. However, we found sCD52 levels also impact TTFT 
among unselected patients with ‘early CLL’. The same study has reported sCD52 levels to 
correlate with the WBC [5]. Looking at patients with either ‘early’ or ‘high-risk’ CLL 
separately, we found no correlation of sCD52 with WBC. However, Albitar et al. addressed 
a mixed population of patients with CLL; in agreement with their findings we also found a 
weak linear correlation with the WBC when looking at the ‘early’ and ‘high-risk’ population 
together. This reflects that sCD52 is a marker of progressive disease emphasizing the 
importance of analyzing patients at specific time points in the disease course.
The predictive impact of sCD52 levels after conventional treatment has also been 
investigated [6,7], however, only analyzing sCD52 levels or CD52 mRNA expression after 
treatment and not at treatment baseline or during treatment. By close disease monitoring 
during conventional as well as ibrutinib treatment, and by our in vitro experiments, we show 
that sCD52 is a potential marker of CLL disease activity, possibly even BCR signaling: 
Following conventional therapy, sCD52 levels decrease in parallel with the blood disease 
burden represented by the WBC, while following BCR-inhibiting treatment with ensuing 
lymphocytosis, it parallels the decreased activity and total decrease in LN disease burden 
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found on ibrutinib [12]. Thus, sCD52 levels correlated with disease activity in a broader 
sense than just WBC, and in the particular setting of ibrutinib-induced lymphocytosis, 
sCD52 levels mirror the active – e.g. BCR activated – disease found in the lymph nodes. In 
light of this, it is not surprising that we found patients with high-sCD52 levels at baseline 
had the most effective lymph node reductions in contrast to the two patients who progressed 
on ibrutinib and had undetectable levels of sCD52 at baseline. Thus, sCD52 levels are 
indicative of treatment response across disease compartments, and can be used to monitor 
the effect of targeted treatment.
Patients with del(17p) have less effect from conventional treatment [16], but do quite well on 
treatment using ibrutinib [17]. Our studied cohorts were too small to allow for a reasonable 
analysis of the effects of del(17p). Also, patients with UM-IGHV have been shown to be 
more sensitive to ibrutinib both in cellular studies [18] and as a result of ibrutinib trials [19]. 
In the ‘ibrutinib-treated’ patients, the two patients progressing on ibrutinib both had UM-
IGHV status and del(17p). Thus, if sCD52 levels reflect BCR pathway activity, then 
theoretically, sCD52 could predict treatment response in this subgroup of patients, but 
further studies are needed.
In conclusion, we confirm sCD52 as a marker for CLL with prognostic impact. We find 
sCD52 levels are related to CLL disease activity and possibly even BCR pathway activation. 
Up until now we have quantified response to conventional treatment by the IWCLL 2008 
response criteria [20], updated in 2013 [21], to be able to classify patients receiving new 
targeted treatment. However, we are in need of better measures for treatment effect in all 
disease compartments as it is cumbersome and resource demanding to do both CT scans, 
bone marrow, and blood examinations in all patients receiving therapy. Thus, in the era of 
BCR-targeted therapy, sCD52 may have a new merit as a marker of disease activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Levels of sCD52 quantified by ELISA. (A) healthy blood donors (n = 45) and patients with 
CLL (n = 86). (B) patients with early CLL (n = 44) and with progressive CLL (progressive 
CLL, n = 42). (C) patients with early CLL and progressive CLL by Binet stage grading A (n 
= 39 and n = 6, early CLL and progressive CLL, respectively), vs. B/C (n = 4 and n = 36, 
early CLL and progressive CLL, respectively). (D) Levels of sCD52 and β2-microglobulin 
(β2m) in patients with early CLL (n = 26) and progressive CLL (n = 30). Statistical analyses 
were performed as unpaired Student’s t tests and linear regression analysis, data were 
logarithmically transformed.
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Levels of sCD52 and time to first treatment (TTFT) in ‘early’ CLL. (A) TTFT in patients 
with ‘early’ CLL divided by the median sCD52 level* (n = 44). (B) TTFT in patients with 
‘early’ CLL at diagnosis based on sCD52 and IGHV mutational status, a sub-group of the 
patients shown in A (n = 34). Statistical analyses were performed as log rank test, 
cumulative incidence rates are shown. M-IGHV: mutated IGHV, UM-IGHV: unmutated 
IGHV. *The median level of sCD52 (274 ng/mL) in ‘early CLL’ patients with a sCD52 level 
above lower limit of quantification in the ELISA found to discriminate best between healthy 
donors and patients with CLL by ROC curve analysis, data not shown.
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Correlation of sCD52 and WBC or lymph node reductions. (A) Before and during treatment 
in patients with ‘high risk’ CLL treated with chemo/chemo-immunotherapy in HOVON68 (n 
= 20, p < .0001). (B) In ‘ibrutinib-treated’ CLL (n = 11, p = ns). (C) Percent lymph node 
reduction by level of sCD52 at treatment baseline below or equal to (sCD52 low) or above 
(sCD52 high) sCD523 median in “ibrutinib-treated CLL” patients at 2, 6, and 12 months (n 
= 25). (D) Levels of sCD52 quantified by western blot in supernatants from anti-IgM bead 
stimulated and vehicle treated CLL PBMC (n = 4). Statistical analyses were performed by 
(A–C) linear mixed models and (D) paired t test, (D) data were logarithmically transformed, 
and (C–D) presented as normalized to pre-values and means with SD are shown. In (C) 
analysis was made by linear mixed models analyzing differences in lymph node reduction at 
all three time points in one model.
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Table 1.
Clinical characteristics of the three CLL cohorts.
Cohort 1 (‘early’) Cohort 2 (‘high-risk’) Cohort 3 (‘ibrutinib-treated’)
n  44  42  25
Treatment naïve, % 100 100  52
High-risk, %  41 100  84
Median age  68  60  68
M, %  48  79  44
Binet B + C, %   9  86  96
WHO 0, %  80  57 ND
M-IGHV, %  57  14  40
del(17p), %   2  26  48
del(11q), %   7  15  24
Tri12, %   5  23  8
Median β2m 191 351 348.5
Median WBC/ALC  27  91 72 (ALC)
%: percentage; n: number; High-risk: (del(17p), del(11q), t(12) and/or unmutated IGHV); M: male gender; M-IGHV: mutated IGHV; del(17p): 
deletion of the short arm of chromosome17; del(11q): deletion of the long arm of chromosome 11; Tri12: Trisomy of chromosome 12; β2m: beta 2 
microglobulin; WBC: white-blood cell count; ALC: absolute lymphocyte count. FISH categories are restricted to those defining high risk CLL.
Leuk Lymphoma. Author manuscript; available in PMC 2019 April 01.
